PredOmix, Core Diagnostics partner to launch OncoVeryx-F

OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection

Astellas receives FDA priority review for Zolbetuximab biologics license application

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients

BDR Pharma's Nilotinib sets a new standard in the treatment of Philadelphia Chromosome-positive leukaemia

Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully

Elekta Unity MR Linac revolutionizes cancer care in India

Astellas submits new drug application for Zolbetuximab in Japan

Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers

Lantern Pharma leverages AI platform to develop breakthrough ADCs with Bielefeld University

Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration

Sun Pharma and Philogen enter into an agreement for commercializing NIDLEGY

Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe

3M to invest nearly $150 million on expanding biopharma filtration capabilities

The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.

Freenome acquires global immunodiagnostics developer Oncimmune

Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection